NAD+ Precursors vs SS-31
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: NMN, NR
NAD+ precursors are not peptides. They are small molecules, mainly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), that the body converts into NAD+, a coenzyme every cell needs to make energy and run repair enzymes. NAD+ falls with age, so these precursors are sold as anti-aging and metabolic supplements. Human trials confirm they reliably raise blood NAD+ levels, but clear proof of real health benefits in people is still missing.
Also: Elamipretide, Bendavia
SS-31 (sequence D-Arg-Dmt-Lys-Phe-NH2), known generically as elamipretide and sold as FORZINITY, is a synthetic tetrapeptide that homes in on the energy-producing machinery inside your cells. It works by binding cardiolipin, a fat unique to the inner mitochondrial membrane, to help mitochondria run cleaner and make more ATP with less oxidative damage. This is the rare research peptide with a real regulatory finish line: the FDA granted it accelerated approval in September 2025 for Barth syndrome, though it has failed several other major trials.
Key Comparison Insights
- SS-31 is FDA approved, while NAD+ Precursors remains in research stages.
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (FDA Approved) compared to NAD+ Precursors (Human Trials).
Detailed Comparison
| Attribute | NAD+ Precursors | SS-31 |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | NAD+ is a workhorse coenzyme for cellular energy metabolism and for enzymes like sirtuins and PARPs that handle DNA repair and stress response. The body builds NAD+ along the salvage pathway: the enzyme NAMPT turns nicotinamide into NMN, and NMNAT enzymes then convert NMN into NAD+. NR enters this route one step upstream, getting phosphorylated into NMN before becoming NAD+. The logic of supplementing is simple: feed the pathway more raw material and you raise the NAD+ pool that declines with age. One wrinkle from recent human work is that gut bacteria may convert some NR and NMN into nicotinic acid before it ever reaches tissues, so the real-world route to higher NAD+ is messier than the textbook diagram. | SS-31 is a cell-permeable, mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane and binds tightly to cardiolipin. Cardiolipin is essential for keeping the membrane's folded cristae structure intact and for organizing the proteins of the electron transport chain that generate ATP. By stabilizing cardiolipin, SS-31 helps preserve cristae shape, reduces the electron leakage that produces reactive oxygen species, and supports more efficient ATP production. Studies also suggest it modulates the membrane's surface electrostatics and can limit opening of the mitochondrial permeability transition pore, a trigger for cell death, though the full mechanistic picture is still being worked out. |
| Common Dosing | Limited community data available See research protocols | 40 mg subcutaneous daily Once daily |
| Administration | Oral (capsules, sublingual) | Subcutaneous injection or IV infusion |
| Typical Duration | Ongoing supplementation | Variable by condition |
| Best Time to Take | Morning or before bed | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The one thing human trials agree on is that these precursors work as NAD+ boosters: randomized placebo-controlled studies show chronic NR is well tolerated and raises NAD+ in healthy middle-aged and older adults, and head-to-head work found NR and NMN both roughly doubled circulating NAD+ over about two weeks, while plain nicotinamide did not. The harder question is whether that biochemical bump translates into anything you would feel. A meta-analysis of NAD+ precursor effects on glucose and lipid metabolism found inconclusive, modest, and inconsistent results, and outcomes vary a lot between people depending on age, health, genetics, and gut microbiome. So the accurate framing is: yes, they raise NAD+ and appear safe short term, but robust evidence that they slow aging, improve metabolic disease, or extend healthspan in humans does not yet exist. Most of the dramatic claims come from mouse studies, not people. | Unlike most peptides in this space, SS-31 has been through extensive human trials, with a mixed but consequential record. In TAZPOWER, a randomized placebo-controlled crossover study in Barth syndrome, elamipretide improved skeletal muscle strength and cardiac stroke volume, and the long open-label extension showed sustained benefit, which ultimately supported FDA accelerated approval in September 2025 as the first treatment for that ultra-rare disease. It has also failed prominently: the Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy missed its primary endpoints on the six-minute walk test, the ReCLAIM trial in dry age-related macular degeneration did not hit its primary endpoints, and a heart-failure trial (PROGRESS-HF) also missed its primary endpoint. Across these studies the drug was generally well tolerated, with mostly mild effects such as injection-site reactions, headache and nausea. The accurate summary is that SS-31 is a validated mitochondrial-targeting peptide with one approved indication and a string of negative trials elsewhere, so its benefit appears to depend heavily on the specific disease. |
Frequently Asked Questions: NAD+ Precursors vs SS-31
What is the difference between NAD+ Precursors and SS-31?
NAD+ Precursors is a anti-aging peptide that nad+ precursors are not peptides. they are small molecules, mainly nicotinamide riboside (nr) and nicotinamide mononucleotide (nmn), that the body converts into nad+, a coenzyme every cell needs to make energy and run repair enzymes. nad+ falls with age, so these precursors are sold as anti-aging and metabolic supplements. human trials confirm they reliably raise blood nad+ levels, but clear proof of real health benefits in people is still missing. SS-31 is a anti-aging peptide that ss-31 (sequence d-arg-dmt-lys-phe-nh2), known generically as elamipretide and sold as forzinity, is a synthetic tetrapeptide that homes in on the energy-producing machinery inside your cells. it works by binding cardiolipin, a fat unique to the inner mitochondrial membrane, to help mitochondria run cleaner and make more atp with less oxidative damage. this is the rare research peptide with a real regulatory finish line: the fda granted it accelerated approval in september 2025 for barth syndrome, though it has failed several other major trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, NAD+ Precursors or SS-31?
Neither is universally "better" - the choice depends on your specific goals. NAD+ Precursors is typically used for anti-aging purposes, while SS-31 is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can NAD+ Precursors and SS-31 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using NAD+ Precursors and SS-31 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.